Multiple Phase 1/2 Cohorts of Nivolumab Monotherapy or Nivolumab Combination Regimens Across Relapsed/Refractory Hematologic Malignancies

Trial Profile

Multiple Phase 1/2 Cohorts of Nivolumab Monotherapy or Nivolumab Combination Regimens Across Relapsed/Refractory Hematologic Malignancies

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Jun 2018

At a glance

  • Drugs Nivolumab (Primary) ; Daratumumab; Ipilimumab; Lirilumab; Pomalidomide
  • Indications Chronic myeloid leukaemia; Hodgkin's disease; Multiple myeloma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Acronyms CheckMate-039
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 08 May 2018 Planned End Date changed from 16 Mar 2020 to 15 Jun 2020.
    • 08 May 2018 Planned primary completion date changed from 15 Mar 2020 to 14 Jun 2020.
    • 05 Dec 2017 Status changed from suspended to recruiting according to a Bristol-Myers Squibb media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top